Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Immunology, Immunotherapy
Erschienen in: Cancer Immunology, Immunotherapy 6/2004

01.06.2004 | Opinion Paper

The effect of aging on cellular immunity against cancer in SR/CR mice

verfasst von: Zheng Cui, Mark C. Willingham

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

SR/CR mice are capable of mounting a highly effective response of leukocytes to large doses of lethal transplantable mouse cancer cells. This response is conferred by a dominant, germline-transmissible mutation independent of sex chromosomes. The resistance can be extended to a broad array of mouse and human cancer cells without harming normal cells. The effector cells are primarily composed of the leukocytes from the innate immune system including macrophages, neutrophils, and natural killer cells. The mice are cancer-free and healthy without detectable abnormality or shortened life span. However, the immune response mechanism of these SR/CR mice is dramatically modulated by the aging process. In this article, we summarize the lessons learned from these mice and discuss possible implications of these findings in our understanding of the effects of aging on the immunity against cancer.
Literatur
1.
Brüünsgaard H, Pedersen BK (2003) Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 23:15PubMed
2.
Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1PubMed
3.
Caruso RA, Speciale G, Inferrera C (1994) Neutrophil interaction with tumour cells in small early gastric cancer: ultrastructural observations. Histol Histopathol 9:295PubMed
4.
Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W, DeLong CJ (2003) Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci U S A 100:6682CrossRefPubMed
5.
Dallegri F, Ottonello L (1992) Neutrophil-mediated cytotoxicity against tumour cells: state of art. Arch Immunol Ther Exp (Warsz) 40:39
6.
Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW (1999) Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 100:34PubMed
7.
Drapier JC, Hibbs JB (1986) Murine cytotoxic activated macrophages inhibit aconitase in tumor cells: inhibition involves the iron-sulfur prosthetic group and is reversible. J Clin Invest 78:790PubMed
8.
Drapier JC, Hibbs JB (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 140:2829PubMed
9.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991CrossRefPubMed
10.
Ehrlich P (1909) Ueber den jetzigen stand der Karzinomforschung. Ned Tijdschr Geneeskd 5:273
11.
Engel AM, Svane IM, Rygaard J, Werdelin O (1997) MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 45:463CrossRefPubMed
12.
Fryling CM, Iwata KK, Johnson PA, Knott WB, Todaro GJ (1985) Two distinct tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line. Cancer Res 45:2695PubMed
13.
Hibbs JB, Taintor RR (1986) Activated macrophage-mediated cytotoxicity: use of the in vitro cytotoxicity assay for study of bioenergetic and biochemical changes that develop in tumor target cells. Methods Enzymol 132:508PubMed
14.
Hibbs JB, Taintor RR, Vavrin Z (1984) Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages. Biochem Biophys Res Commun 123:716PubMed
15.
Hunig T (1983) T-cell function and specificity in athymic mice. Immunol Today 4:84
16.
Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA (1984) Functional T cells in athymic nude mice. Proc Natl Acad Sci U S A 81:886PubMed
17.
Maleckar JR, Sherman LA (1987) The composition of the T cell receptor repertoire in nude mice. J Immunol 138:3873PubMed
18.
Mizel SB, DeLarco JE, Todaro GJ, Farrar WL, Hilfiker ML (1980) In vitro production of immunosuppressive factors by murine sarcoma virus-transformed mouse fibroblasts. Proc Natl Acad Sci U S A 77:2205PubMed
19.
Romeo DS, Mizel SB (1989) Partial purification of an immunosuppressive protein from a human tumor cell line and analysis of its relationship to transforming growth factor beta. Cell Immunol 122: 483PubMed
20.
Rygaard J, Povlsen CO (1974) Is immunological surveillance not a cell-mediated immune function? Transplantation 17:135PubMed
21.
Rygaard J, Povlsen CO (1974) The mouse mutant nude does not develop spontaneous tumours: an argument against immunological surveillance. Acta Pathol Microbiol Scand [B] Microbiol Immunol 82:99
22.
Shah AH, Lee C (2000) TGF-beta-based immunotherapy for cancer: breaching the tumor firewall. Prostate 45:167CrossRefPubMed
23.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107PubMed
24.
Sherwin SA, Twardzik DR, Bohn WH, Cockley KD, Todaro GJ (1983) High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 43:403PubMed
25.
Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661CrossRefPubMed
26.
Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA (2000) Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192:755CrossRefPubMed
27.
Stutman O (1978) In: Fogh J, Giovanella BC (eds) The nude mouse in experimental and clinical research. Academic, New York, pp 411–435
28.
Stutman O (1979) Spontaneous tumors in nude mice: effect of the viable yellow gene. Exp Cell Biol 47:129PubMed
29.
Thomas L (1959) In: Lawrence HS (ed) Cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York, pp 529–532
30.
Yim CY, McGregor JR, Kwon OD, Bastian NR, Rees M, Mori M, Hibbs JB, Samlowski WE (1995) Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor. J Immunol 155:4382PubMed
31.
Yoshida M, Matsuzaki H, Sakata K, Takeya M, Kato K, Mizushima S, Kawakita M, Takatsuki K (1992) Neutrophil chemotactic factors produced by a cell line from thyroid carcinoma. Cancer Res 52:464PubMed
Metadaten
Titel
The effect of aging on cellular immunity against cancer in SR/CR mice
verfasst von
Zheng Cui
Mark C. Willingham
Publikationsdatum
01.06.2004
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 6/2004
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0488-2

Weitere Artikel der Ausgabe 6/2004

Cancer Immunology, Immunotherapy 6/2004 Zur Ausgabe

Original Article

A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells

Original Article

Dendritic cells are dysfunctional in patients with operable breast cancer

Original Article

Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies

Original Article

Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines

Original Article

MHC class II and CD80 tumor cell–based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain

Short Communication

Detection of circulating tumor lysate–reactive CD4+ T cells in melanoma patients

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise